Investor Presentation - First Six Months of 2021

5 Investor presentation First six months of 2021 Sales growth of 12% driven by both operating units and all therapy areas Reported geographic sales split for the first half of 2021 Reported therapy area sales and growth for the first half of 2021 DKK billion ■Insulin ■GLP-1 Other diabetes Obesity Biopharm Growth at CER DKK billion North America Operations International Operations Growth at CER 12% 30% 1% 34% 7% 42 22 72 13% 35 28 221 11% 21 60 11% International Operations 13% 48 36 14 24 16% 12% 46% 6% 11% 7 12 24% IO 44% NAO 27% IO 4% NAO 12% -11% 0 0 IO EMEA China ROW NAO Total 1 GLP-1 Insulin Obesity Biopharm 1 'Other diabetes' is included in Total IO: International Operations; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; RoW: Rest of World; NAO: North America Operations Note: Unless otherwise specified, sales growth rates are at CER Novo NordiskⓇ

View entire presentation